Robert Huber was born in 1937 in Munich. He studied chemistry at the Technische Universität München (TUM), where he also completed his Ph.D. and habilitation. Since 1972, he has been a member of the Max-Planck-Gesellschaft and Director at the Max-Planck-Institut für Biochemie until his retirement in 2005. Since 1976, he also serves at the TUM as a Professor. He holds appointments as Guest Professor at the Universität Duisburg-Essen (Germany), the Cardiff University (Great Britain), the Universidad Autonoma de Barcelona (Spain), and the Seoul National University (Korea). He serves as a member of the Board and/or Scientific Advisory Board of a number of pharmaceutical and crop science companies, and he is co-founder of two companies, Proteros and Suppremol, located in Martinsried and offering services for drug discovery and development and for the development of novel therapies for autoimmune diseases, respectively. Huber has made major contributions to the understanding of the structure and function of biological macromolecules. He has studied proteases and their natural and synthetic inhibitors, metalloenzymes (iron, nickel, molybdenum, copper), proteins of the immune system (antibodies and antibody receptors), protein hormones and their receptors, protein kinases, enzymes of amino acid biosynthesis, enzymes of cofactor and vitamin biosynthesis and proteins of energy and electron transfer. In addition, he has contributed to the development of instruments for data collection and to methods in protein crystallography, particularly Patterson methods, graphic methods, and refinement, to the use of electron rich metal clusters, and most recently to the methods and instruments for crystal improvement. He has been honoured by numerous honorary doctorates, professorships, memberships in learned societies and awards, including the Otto-Warburg Medal, the Emil von Behring Medal, the Sir Hans Krebs Medal, the The Linus Pauling Medal, Max Tishler Prize and, in 1988, the Nobel Prize for Chemistry together with H. Michel and J. Deisenhofer.
Share on twitter
Share on facebook
Share on linkedin
Share on social media
Tuesday, July 12 |
The century of vision: Protein structures for drug design and development: The proteasome and other cage-forming proteases
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., pop-up notification choices).The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.